Randomized phase II study of two different schedules of gemcitabine and oral S-1 in <font color="red">chemo_4</font> <font color="red">-_4</font> <font color="red">naïve_4</font> <font color="red">patients_4</font> <font color="red">with_4</font> <font color="red">advanced_4</font> <font color="red">non_4</font> <font color="red">-_4</font> <font color="red">small_4</font> <font color="red">cell_4</font> <font color="red">lung_4</font> <font color="red">cancer_4</font> <font color="red">._4</font> 
<br>
<br> INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in <font color="red">chemo_3</font> <font color="red">-_3</font> <font color="red">naïve_3</font> <font color="red">non_3</font> <font color="red">-_3</font> <font color="red">small_3</font> <font color="red">cell_3</font> <font color="red">lung_3</font> <font color="red">cancer_3</font> <font color="red">patients_3</font> <font color="red">._3</font> <font color="red">
<br>_1</font> METHODS <font color="red">Patients_5</font> <font color="red">with_5</font> <font color="red">chemo_5</font> <font color="red">-_5</font> <font color="red">naïve_5</font> <font color="red">stage_5</font> <font color="red">IIIB_5</font> <font color="red">/_5</font> <font color="red">IV_5</font> <font color="red">non_5</font> <font color="red">-_5</font> <font color="red">small_5</font> <font color="red">cell_5</font> <font color="red">lung_5</font> <font color="red">cancer_5</font> <font color="red">were_2</font> <font color="red">randomized_2</font> <font color="red">into_2</font> <font color="red">two_2</font> <font color="red">treatment_2</font> <font color="red">arms_2</font> <font color="red">._2</font> <font color="red">Patients_1</font> <font color="red">were_1</font> <font color="red">given_1</font> <font color="red">oral_1</font> <font color="red">S-1_1</font> <font color="red">(_1</font> <font color="red">60_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">m_1</font> <font color="red">/_1</font> <font color="red">d_1</font> <font color="red">,_1</font> <font color="red">twice_1</font> <font color="red">a_1</font> <font color="red">day_1</font> <font color="red">)_1</font> <font color="red">from_1</font> <font color="red">days_1</font> <font color="red">1_1</font> <font color="red">to_1</font> <font color="red">14_1</font> <font color="red">with_1</font> <font color="red">gemcitabine_1</font> <font color="red">(_1</font> <font color="red">1000_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">m_1</font> <font color="red">/_1</font> <font color="red">d_1</font> <font color="red">)_1</font> <font color="red">on_1</font> <font color="red">days_1</font> <font color="red">1_1</font> <font color="red">and_1</font> <font color="red">8_1</font> <font color="red">(_1</font> <font color="red">arm_1</font> <font color="red">A_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">on_1</font> <font color="red">days_1</font> <font color="red">8_1</font> <font color="red">and_1</font> <font color="red">15_1</font> <font color="red">(_1</font> <font color="red">arm_1</font> <font color="red">B_1</font> <font color="red">)_1</font> <font color="red">._1</font> <font color="red">This_1</font> <font color="red">cycle_1</font> <font color="red">was_1</font> <font color="red">repeated_1</font> <font color="red">every_1</font> <font color="red">21_1</font> <font color="red">days_1</font> <font color="red">._1</font> 
<br> RESULTS <font color="red">A_3</font> <font color="red">total_3</font> <font color="red">of_3</font> <font color="red">80_4</font> <font color="red">patients_4</font> <font color="red">were_2</font> <font color="red">entered_2</font> <font color="red">in_2</font> <font color="red">this_2</font> <font color="red">trial_2</font> <font color="red">._2</font> The primary end point of this study was response rate . The response rates of arm A and arm B were 22.0 and 28.9% , respectively ( p = 0.606 ) . Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months , respectively . The toxicity profile was relatively mild and did not differ very much between two arms . 
<br> CONCLUSION The combination of gemcitabine and S-1 was determined to be feasible and effective for <font color="red">advanced_1</font> <font color="red">non_1</font> <font color="red">-_1</font> <font color="red">small_1</font> <font color="red">cell_1</font> <font color="red">lung_1</font> <font color="red">cancer_1</font> <font color="red">._1</font> We selected arm B for further studies because of its higher response rate and survival data .